Stay updated on HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial
Sign up to get notified when there's something new on the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page.

Latest updates to the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study record was updated to standardize the Intervention/Treatment heading, add the investigator name Xuexin He and last-verified status, and include new help sections (How to Read a Study Record, Common Questions, How to Join a Study) with a revision tag Revision: v3.6.0. Removed the older items 'Intervention / Treatment', the full investigator attribution ('xuexin he, Second Affiliated Hospital, School of Medicine, Zhejiang University'), and the previous revision tag (Revision: v3.5.5).SummaryDifference1%

- Check21 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous v3.5.4. This indicates a minor backend or UI update rather than a change to study details.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page now shows Revision: v3.5.4, indicating a small release of the site software; no study data or visible content changes are introduced.SummaryDifference0.0%

- Check49 days agoChange DetectedA Last known status entry was added, listing the investigator and affiliation with a date and verification status. This update adds metadata about who last verified the record and when.SummaryDifference0.4%

- Check63 days agoChange DetectedThe page’s display/release revision indicator was updated from v3.5.2 to v3.5.3, reflecting a platform/version change without affecting the study information content.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page.